Our findings revealed the pivotal role of LncNFYB in cell cycle control and hyperplasia in RA-FLS and implicated the LncNFYB/ANXA2/ERK1/2 axis as a potential therapeutic target for RA. This evidence concerns the gene MAPK3 and rheumatoid arthritis.